DRKS00031527招募中不适用
Biochemical and genetic markers in liver diseases
niversitätsklinikum Heidelberg0 个研究点目标入组 500 人开始时间: 2023年3月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Liver disease
排除标准
- •Lack of legal capacity, lack of consent, prison, patients < 18 years
研究者
相似试验
Unknown
不适用
Biochemical and Genetic Markers in Liver DiseasesBiochemical and Genetic Markers in Liver DiseasesNCT01706614University Hospital Heidelberg500
招募中
不适用
The relationship between the biomarker, and liver, bile duct or pancreas disease.the disease of liver, biliary, and pancreasJPRN-UMIN000031568ara medical university200
进行中（未招募）
不适用
Investigation of treatment for people with liver disease who were born with a birth defect inherited from their parents which means that their body cannot make normal bile acids, which help the body break down and use the fat and vitamins from the foods we eatPatients with inborn errors of bile acid synthesis and metabolismMedDRA version: 14.0Level: PTClassification code 10070882Term: Inborn error in primary bile acid synthesisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004259-38-Outside-EU/EEAAsklepion Pharmaceuticals, LLC82
招募中
Unknown
Evaluation of molecular biomarkers for hepatocellular carcinoma (HCC) therapyLiver CirrhosisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonCancer - LiverLiver CancerHepatocellular CarcinomaACTRN12623000762651A/Prof Adam Testro150
招募中
不适用
liver signal profiling and blood marker research for non-alcoholic fatty liver diseasesnonalcoholic fatty liver diseasesJPRN-UMIN000013323Saga Medical School Hiroshima University Yokohama City University Graduate School of Medicine Takeda Pharmaceutical Company100